Interferon Interactions: What Studies Report on Alcohol, Caffeine and Food

What the interferon "interaction" question actually asks

Interferons are a family of signalling proteins produced by cells during viral infection and immune activation, and they are also used pharmacologically — a review of peginterferon alfa-2b combined with ribavirin described that pairing in the context of chronic hepatitis C management (PMID 15482168). Because interferon exists both as an endogenous signal and as an administered protein, questions about "interactions" with alcohol, caffeine or food actually cover two very different literatures.

The first literature asks whether a substance changes interferon biology — whether it raises or lowers interferon expression, alters the cells that produce interferon, or shifts interferon-driven inflammation. Studies of ethanol in the nervous system fall here: researchers reported that ethanol induced interferon expression in neurons via TRAIL, with astrocyte-to-neuron signalling identified as the route (PMID 30610351). The second literature asks whether a substance changes the handling or the effects of administered interferon — absorption, clearance, efficacy or tolerability. In the verified body of work summarised on this page, the first literature is populated and the second is largely empty.

Where no interaction study exists, that is stated plainly below, and the reasoning researchers apply in its absence is labelled as mechanistic reasoning rather than evidence. This page is for educational purposes only and is not medical advice; consult a licensed physician for questions about any substance, medication or medical condition.

Alcohol and interferon biology: what the studies examined

Brain and astrocyte models

The most direct alcohol-and-interferon link in this evidence set is neural. The study of ethanol in neurons reported that interferon expression was induced through TRAIL and that astrocytes signalled to neurons to produce that effect (PMID 30610351). A separate 2025 report examined astrocyte immune activation in the nucleus accumbens under alcohol dependence, describing an immune-activated astrocyte state in that brain region (PMID 41192645). Together these two reports place astrocytes at the centre of how alcohol exposure was observed to reshape local immune signalling in animal and cellular models (PMID 30610351).

Neither report was a study of administered interferon in people who also consumed alcohol. Researchers in these models measured endogenous interferon-related signalling after ethanol exposure, which is a question about alcohol's effect on the interferon system rather than a drug-drug interaction (PMID 41192645).

Innate immune cells

Alcohol's effects on innate immune cells have also been examined. A 2022 study reported that ethanol consumption induced nonspecific inflammation and functional defects in alveolar macrophages, describing impaired macrophage function alongside an inflammatory shift (PMID 35380939). A 2025 preprint reported that chronic alcohol consumption drove inflammaging and transposon derepression in hematopoietic stem and progenitor cells (PMID 41497601); because it is a preprint, it had not completed peer review at posting, which researchers typically flag when weighing such findings.

Mechanistic reasoning, labelled as such: derepressed transposable elements can generate cytosolic nucleic acids that innate sensors recognise, and that sensing pathway is the same one that drives type I interferon transcription. The preprint reported transposon derepression and an inflammaging phenotype in hematopoietic stem and progenitor cells (PMID 41497601); the step from that observation to a predicted interferon output in a person consuming alcohol is inference, not a measured result.

Liver models

Most alcohol immunology sits in liver research. A 2022 review of the pathogenesis of alcohol-associated liver disease set out the multi-hit picture of hepatocyte injury, gut-derived signals and immune activation that the field uses as its framework (PMID 36340300). At the organelle level, researchers reported that loss of hepatic DRP1 exacerbated alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation (PMID 35698731).

Lymphocyte studies are directly relevant to interferon-gamma, which natural killer cells produce. One study reported that suppression of natural killer cell activity by regulatory NKT10 cells aggravated alcoholic hepatosteatosis (PMID 29163491). A 2026 report described glutamate excreted by LepR-positive bone-marrow mesenchymal stromal cells mitigating alcohol-associated liver disease by promoting IL-1R2-positive monocyte migration (PMID 42315151). These are mechanistic studies of alcohol-related liver immunity; none of them administered interferon alongside alcohol (PMID 29163491).

Cytokine administration in an alcohol model

One study in this set did give an exogenous cytokine in an alcohol context: researchers reported that G-CSF increased calprotectin expression, liver damage and neuroinflammation in a murine model of alcohol-induced acute-on-chronic liver failure (PMID 38419842). G-CSF is not an interferon, so the result does not transfer; it is cited here only because it is the closest example in the verified set of a cytokine being administered on top of alcohol exposure and producing a measured change in liver and brain readouts (PMID 38419842).

Alcohol and interferon-based therapy: what is and is not in the evidence

Interferon alfa products have been used with ribavirin in chronic hepatitis C, and a review of peginterferon alfa-2b with ribavirin covered that combination (PMID 15482168). No study in the verified set for this page tested alcohol intake as a variable during interferon therapy, measured interferon pharmacokinetics after alcohol, or reported response rates stratified by drinking. That gap is stated plainly rather than filled by extrapolation.

Mechanistic reasoning, labelled as such: the alcohol literature above describes liver injury pathways and immune-cell dysfunction (PMID 36340300), and the interferon-alfa literature concerns a liver-directed antiviral setting (PMID 15482168). Researchers reason about overlap between those two pictures, but overlap of organ and cell type is a hypothesis about where an interaction could occur — it is not a measured interaction, and this page draws no conclusion about combining them.

Caffeine and interferon: the two relevant reports

Caffeine appears twice in this evidence set. A 2022 report in the interferon and cytokine research literature described caffeine citrate protecting against sepsis-associated encephalopathy and inhibiting the UCP2/NLRP3 axis in astrocytes (PMID 35420462). The study's readouts concerned an inflammasome pathway in astrocytes rather than interferon signalling directly, and no interferon was administered.

The closest co-exposure study examined glutamate-mediated effects of caffeine and interferon-gamma on mercury-induced toxicity, meaning caffeine and interferon-gamma were studied in the same experimental system (PMID 28350110). That report is a cell-level toxicology model of a heavy metal exposure, and researchers framed glutamate handling as the shared mechanism (PMID 28350110).

What is absent: no verified study measured caffeine's effect on interferon clearance, injection-site reactions, flu-like symptom scores, or interferon efficacy in humans. Statements that coffee "boosts" or "blunts" interferon are not supported by anything in this set; the only interferon-adjacent caffeine findings are the astrocyte inflammasome report (PMID 35420462) and the interferon-gamma co-exposure model (PMID 28350110).

Food, fasting and meal timing: no interaction studies in this set

No study among the verified papers examined interferon with food, fasted versus fed states, macronutrient composition, grapefruit juice, or intermittent fasting. There is no finding to report, and none is invented here.

Mechanistic reasoning, labelled as such: interferons are proteins, and protein biologics are not administered orally in the settings described in the peginterferon alfa-2b and ribavirin review (PMID 15482168), so the classic oral-drug food effects — gastric pH, bile-salt solubilisation, first-pass metabolism — are the reasons researchers give for expecting meals to matter less than they do for small-molecule tablets. That reasoning is a prediction about a mechanism, not a measured food-effect study, and nothing in this evidence set tested it.

Other compounds researchers have studied alongside interferon or in interferon-adjacent models

Interferon Interaction Research and Adverse Events: What Studies Report

Adverse or harmful outcomes in this evidence set were reported in the substance-exposure models, not in interaction trials. The alveolar macrophage study reported nonspecific inflammation together with functional defects after ethanol consumption (PMID 35380939). The hepatic DRP1 study reported exacerbated alcoholic hepatitis with megamitochondria and mitochondrial maladaptation when DRP1 was lost (PMID 35698731). The NKT10 study reported aggravated alcoholic hepatosteatosis when natural killer cell activity was suppressed (PMID 29163491).

In the one cytokine-administration model, researchers reported worse outcomes rather than better ones: G-CSF increased calprotectin expression, liver damage and neuroinflammation in alcohol-induced acute-on-chronic liver failure in mice (PMID 38419842). The broader pathogenesis review placed such findings within alcohol-associated liver disease progression (PMID 36340300). None of these reports describes adverse events from combining interferon with alcohol, caffeine or food in humans, because no such study appears in this set (PMID 15482168).

How researchers describe the limits of this evidence

• Species and system. The ethanol-interferon, macrophage, astrocyte and liver findings came from animal and cell models, including the neuronal TRAIL study (PMID 30610351) and the murine ACLF model (PMID 38419842).
• Direction of the question. Most reports asked what a substance did to interferon-related biology, not what it did to administered interferon (PMID 35380939).
• Publication stage. One alcohol-and-inflammaging report was a preprint (PMID 41497601).
• Different cytokine. G-CSF and interferon are distinct molecules, so the ACLF result does not generalise to interferon (PMID 38419842).
• Silent areas. Food timing, fasting, alcohol during therapy and human caffeine pharmacokinetics were not examined; the therapeutic context is described only in review form (PMID 15482168).

Readers comparing sources may notice claims elsewhere that are stated far more confidently than the underlying reports allow. In this evidence set the strongest statements that can be made are descriptive: ethanol changed interferon expression in a neuronal model (PMID 30610351), alcohol dependence was associated with astrocyte immune activation in the nucleus accumbens (PMID 41192645), and caffeine has been studied alongside interferon-gamma in one toxicology model (PMID 28350110). Anything beyond that is mechanistic reasoning, and this page labels it that way. Again, this material is educational only and is not medical advice; a licensed physician is the appropriate source for individual questions.

References

• Pathogenesis of Alcohol-Associated Liver Disease (Journal of Clinical and Experimental Hepatology, 2022)
• Chronic alcohol consumption drives inflammaging and transposon derepression in hematopoietic stem and progenitor cells (bioRxiv, 2025)
• Ethanol Consumption Induces Nonspecific Inflammation and Functional Defects in Alveolar Macrophages (American Journal of Respiratory Cell and Molecular Biology, 2022)
• Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation (Hepatology, 2023)
• Caffeine Citrate Protects Against Sepsis-Associated Encephalopathy and Inhibits the UCP2/NLRP3 Axis in Astrocytes (Journal of Interferon & Cytokine Research, 2022)
• Peginterferon-alpha(2b) and ribavirin (Expert Review of Anti-infective Therapy, 2004)
• Alcohol dependence-induced astrocyte immune activation in the nucleus accumbens (Neurobiology of Disease, 2025)
• Ethanol induces interferon expression in neurons via TRAIL: role of astrocyte-to-neuron signaling (Psychopharmacology, 2019)
• Glutamate-mediated effects of caffeine and interferon-γ on mercury-induced toxicity (International Journal of Molecular Medicine, 2017)
• Suppression of Natural Killer Cell Activity by Regulatory NKT10 Cells Aggravates Alcoholic Hepatosteatosis (Frontiers in Immunology, 2017)
• Glutamate excreted by LepR⁺ BM-MSCs mitigates alcohol-associated liver disease by promoting IL-1R2⁺ monocyte migration (Clinical and Molecular Hepatology, 2026)
• G-CSF increases calprotectin expression, liver damage and neuroinflammation in a murine model of alcohol-induced ACLF (Frontiers in Cell and Developmental Biology, 2024)